QLi5 Therapeutics develops next-generation non-covalent proteasome inhibitors that exhibit strong anti-tumor activity against multiple myeloma and solid tumors, while minimizing side effects and improving tissue distribution. The company's platform addresses unmet medical needs in the treatment of cancers and inflammatory autoimmune disorders through enhanced selectivity and pharmacokinetic properties.
Funding
Funding not disclosed
Founders
Product
Problem
Current proteasome inhibitors used in cancer therapy can cause significant side effects and may not distribute effectively to tumor tissues. This can limit their efficacy and tolerability, particularly in patients with multiple myeloma and solid tumors. There is a need for more selective and better-tolerated proteasome inhibitors with improved pharmacokinetic properties.
Solution
QLi5 Therapeutics is developing a new class of non-covalent proteasome inhibitors designed to overcome the limitations of existing therapies. These next-generation inhibitors exhibit strong anti-tumor activity against multiple myeloma and solid tumors while minimizing side effects. The compounds are designed for improved tissue distribution and enhanced selectivity, potentially leading to better patient outcomes and a wider range of applications in cancers and inflammatory autoimmune disorders. The non-covalent mode of action and optimized pharmacokinetic properties aim to reduce accumulation in blood cells and improve drug delivery to target tissues.
Target Audience
The primary target audience includes patients with multiple myeloma, solid tumors, and inflammatory autoimmune disorders, as well as oncologists and hematologists seeking more effective and better-tolerated treatment options.
Features
- Non-covalent binding mechanism to the proteasome
- Demonstrated anti-tumor activity against multiple myeloma and solid tumors
- Improved pharmacokinetic (PK) properties and tissue distribution
- Reduced accumulation in blood cells compared to existing inhibitors
- Potential for application in hematologic malignancies, inflammation, and autoimmune diseases